Walgreens Holding Co

Latest Report Overview

Walgreens Holding Co $WBA reported a net loss of $175 million, or $(0.20) per diluted share, for the third quarter of fiscal 2025 ended May 31, 2025, compared to net earnings of $344 million in the year-ago period. Quarterly sales increased 7.2% to $38.99 billion, driven primarily by growth in pharmacy sales. However, gross profit decreased slightly due to retail weakness, and operating income remained under pressure at $53 million. The company’s performance reflects the ongoing execution of its Footprint Optimization Program, which closed 423 stores in the nine months ended May 31, 2025, alongside persistent challenges in the U.S. retail segment including lower sales in discretionary categories. The U.S. Healthcare segment showed improvement with adjusted operating income of $54 million versus an operating loss in the year-ago quarter, driven by VillageMD and Shields, though the segment remains the focus of ongoing divestiture efforts. Management highlighted that the merger agreement with affiliates of Sycamore Partners, signed on March 6, 2025, remains the primary path forward, with an expected closure in the second half of calendar year 2025. The company has suspended its quarterly cash dividend and continues to monetize non-core assets, including further reducing its stake in Cencora, to focus on liquidity and core retail pharmacy stability.

Key Takeaways for Walgreens Holding Co

• WBA signed a definitive Merger Agreement on March 6, 2025, with affiliates of Sycamore Partners to be acquired for $11.45 per share plus Divested Asset Proceed Rights.
• The Footprint Optimization Program continues with 423 store closures in the first nine months of fiscal 2025, aiming for a total reduction of 1,200 to 1,300 stores by end of fiscal 2027.
• The Board suspended the quarterly cash dividend on January 30, 2025, citing a need to preserve liquidity and support long-term turnaround efforts.
• Continued impairment of the U.S. Healthcare segment persists, with significant goodwill and intangible asset impairment charges recorded across VillageMD, U.S. Retail Pharmacy, and CareCentrix reporting units in fiscal 2025.
• Ownership in Cencora was reduced to 5% by May 31, 2025, as the company settles VPF derivative contracts and monetizes equity method investments to improve liquidity.
• A settlement was reached with the U.S. Department of Justice on April 18, 2025, regarding opioid dispensing, resulting in a $300 million payment over six years plus contingent amounts.
• The retail environment remains challenging, with comparable retail sales declining 2.4% in Q3 2025 due to a weak cough, cold, and flu season and lower discretionary spending.